Skip to main content
Northwestern University Feinberg School of Medicine
The Ken & Ruth Davee Department of Neurology
Skip to main content

Multiple Sclerosis & Neuroimmunology Trials

As part of an academic medical center, the Division of Multiple Sclerosis & Neuroimmunology at Northwestern University Feinberg School of Medicine aims to improve human health through scientific research. Clinical trials test or study drugs, surgical procedures, medical devices or interventions with human subjects. They look to determine their safety and effectiveness in relation to treating specific diseases. Clinical trials are part of clinical research and are at the heart of all medical advances.

The following searchable list includes all the multiple sclerosis and neuroimmunology clinical trials currently looking for participants.

Trials
North American Registry for Care and Research in Multiple Sclerosis (NARCRMS) Study
This is a non-interventional study (i.e. no study drug)

NARCRMS is a highly collaborative effort involving investigators, industry, and, mostimportantly, patients. The goal of this effort is to make informati…

This is a non-interventional study (i.e. no study drug)

NARCRMS is a highly collaborative effort involving investigators, industry, and, mostimportantly, patients. The goal of this effort is to make information on all aspects of MS availableto all stakeholders in real-time. The feedback that patients will eventually receive will allowthem to evaluate themselves as compared to the whole cohort, and permit themselves to beactive participants towards their care.

The NARCRMS database is unique for the following reasons:

1. This is the only database in MS that is North American in scope.

2. This is the only database that is all encompassing. It examines every aspect of MS;clinical, imaging, biomarkers, pathology, healthcare economics, and pharmacotherapy.

3. This is the only database that makes available to all stakeholders in an anonymousformat the entire dataset, including imaging, in real-time.4. This is the only database that allows examination of therapeutic agents in a phase 4setting, after the launch of the agent.

Inclusion Criteria:

  • Age 18 to 65 years.
  • Relapsing-Remitting or progressive MS with clear date ofMS onset within 15 years.
  • EDSS of 6.5 or less.
  • Evidence of Clinical Isolated Syndrome.
  • Willingness to participate and contribute data on an ongoing basis

Exclusion Criteria:

  • Unclear date of onset. Onset with symptoms of fatigue,malaise, pain and other vague symptoms without adefinable neurological symptom-onset date.
  • Concomitant confounding disorders like neuromyelitisoptica and idiopathic isolated transverse myelitis, and/orknown autoimmune disorders that can cause neurologicaldisorders, etc.
  • Unwilling to participate for ongoing follow up collection ofdata.
  • Any other factor that in the opinion of the principalinvestigator will render the individual unsuitable forparticipation.

Cohen, Bruce ArnoldCohen, Bruce Arnold
  • Map it Lavin Pavillion 259 E. Erie St., Suite 19-100
    Chicago, IL
STU00201852
More Info

For more information on this study please contact us:

Joslin, Benjamin
Copy
Back to top